Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia (Trial Using Systemic Bevacizumab to Treat HHT, TrUST-HHT)

NCT04404881 is registered in ClinicalTrials.gov with Hanny Al-Samkari, MD as lead sponsor.

NCT NCT04404881
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04404881 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Bevacizumab for Chronic Bleeding and Iron Deficiency Anemia in Hereditary Hemorrhagic Telangiectasia (Trial Using Systemic Bevacizumab to Treat HHT, TrUST-HHT)
Lead sponsor
Hanny Al-Samkari, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 23, 2020
Completion date
February 1, 2027
Enrollment
33 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary hemorrhagic telangiectasia